Graphic: Cathleen Heard Twenty years ago, venture capitalists knew little about biotechnology. The scientific community knew only a fraction more. "With respect to immune system hormones, not a single interleukin gene had been cloned by 1981. No cytokine had actually been purified to molecular homogeneity," writes Steven Gillis, chairman and CEO of Corixa Corp., a Seattle-based immunotherapeutics company.1 Gillis recollects that preclinical efficacy data in animals did not exist for the earliest
| Graphic: Cathleen Heard |
 |
"Naïvete was a wonderful catalyst for the birth of the biotechnology revolution," Gillis recalls in the same article. "Scientist entrepreneurs knew little of the technological pitfalls ... likewise, investors had little appreciation for the rigors of clinical trials, the politics of the Food and Drug Administration [FDA] advisory panels, and the massive impact these vagaries would play on their rate of return ...
Genetics and tolerance shake up how alcohol affects each person, creating a unique cocktail of experiences.
View this Issue
Experts from the Women’s Brain Foundation and bit.bio will explore the importance of sex-specific in vitro models for neurological research and drug discovery.
Discover how scientists are designing the next groundbreaking vaccines against infectious diseases.
In this webinar, Linghua Wang and Jeremy Goecks will talk about technology that enables new approaches for a better understanding of tumors on a cellular, spatial, and environmental level.
Explore how researchers use organoids to understand tissue regeneration and develop novel therapies.
Collaborative project with world leader in AI computing demonstrates Artificial workflows and model integration for self-driving generative virtual screening in drug discovery. Company also announces key accreditations in recognition of excellence in data security, AI innovation, and commitment to continuous improvement.
Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of capsid titer, genome titer, and percentage of full capsids in purified or unpurified (crude lysate) samples.
Tailored nucleic acid extraction and amplification methods help scientists overcome the challenges of detecting Mycoplasma contamination in advanced therapy medicinal products.
